Taken together, these results suggest that FB is able to exert pro-apoptotic effects, by interfering with the expression of both PI3K/AKT pathway and the anti-apoptotic protein BCL-XL, which may be an advantage as suggested by Qian et al. They revealed that dual inhibition of PI3K/AKT and BCL-XL had a synergistic effect on apoptosis, proposing that a combined therapy inhibiting these two important pathways would be a major benefit in lung cancer [26]. The gene discussed is BCL2L1; the disease is lung carcinoma.